Patent: 10,507,244
✉ Email this page to a colleague
Summary for Patent: 10,507,244
Title: | Anti-TIGIT antigen-binding proteins and methods of use thereof |
Abstract: | Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods. |
Inventor(s): | Hicklin; Daniel (Montclair, NJ), Winston; William (Marlborough, MA), Seidel-Dugan; Cynthia (Belmont, MA), Nielson; Nels P. (Lebanon, NH) |
Assignee: | Potenza Therapeutics, Inc. (Cambridge, MA) |
Application Number: | 15/627,161 |
Patent Claims: | see list of patent claims |
Details for Patent 10,507,244
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-10-01 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-10-01 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 12/22/2014 | ⤷ Try a Trial | 2035-10-01 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 10/04/2017 | ⤷ Try a Trial | 2035-10-01 |
Bristol-myers Squibb Company | OPDIVO | nivolumab | Injection | 125554 | 08/27/2021 | ⤷ Try a Trial | 2035-10-01 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |